Combination treatment shows promise in BRCA-, PALB2-mutated breast cancer

SAN ANTONIO — Combining a poly(ADP-ribose) polymerase inhibitor with a PD-1 antibody in a nonchemotherapy regimen for BRCA-mutated breast cancer showed promise, according to a presenter here.
Erica L. Mayer, MD, MPH, a medical oncologist from Dana-Farber Cancer Institute, presented the ER-positive cohort of the phase 2 prospective study during a rapid-fire session at the San Antonio Breast Cancer Symposium. The other two arms of the study will include triple-negative breast cancer.
The trial includes BRCA1, BRCA2 and PALB2 mutations treated with the regimen prior to surgery.
Three of the

SAN ANTONIO — Combining a poly(ADP-ribose) polymerase inhibitor with a PD-1 antibody in a nonchemotherapy regimen for BRCA-mutated breast cancer showed promise, according to a presenter here.
Erica L. Mayer, MD, MPH, a medical oncologist from Dana-Farber Cancer Institute, presented the ER-positive cohort of the phase 2 prospective study during a rapid-fire session at the San Antonio Breast Cancer Symposium. The other two arms of the study will include triple-negative breast cancer.
The trial includes BRCA1, BRCA2 and PALB2 mutations treated with the regimen prior to surgery.
Three of the